What options for treatment of hereditary breast cancer?

Lancet

Volumn 359, Issue 9316, 2002, Pages 1451-1452

  Narod, Steven ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; TAMOXIFEN;

BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; FAMILIAL CANCER; GENETIC SCREENING; HUMAN; MAMMOGRAPHY; MASTECTOMY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0037181715     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08465-9     Document Type: Note

References (12)

1. Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
2. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
3. Re: Magnetic resonance imaging and mammography in women with a high hereditary risk of breast cancer
4. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
5. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
6. Case-control study of factors associated with failure to detect breast cancer by mammography
7. Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers
8. The natural history of breast carcinoma - What have we learned from screening?
9. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results
10. Comparison of breast magnetic resonance imaging, mammography and ultrasound for surveillance of women at high risk for hereditary breast cancer
11. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
12. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer